Le Lézard
Classified in: Health
Subject: SVY

FDAnews Announces -- The Drug GMP Report Newsletter Subscription


FALLS CHURCH, Va., March 27, 2020 /PRNewswire-PRWeb/ -- Drug GMP Report
An FDAnews Newsletter
https://www.fdanews.com/subscribe-now/drug-gmp-report

Inspection hotspots... certification... procedures... electronic data requirements... evolving trends in drug GMP enforcement...

Want access to the inner workings of the FDA or a trusted friend there to share insights into the interpretation and enforcement of cGMPs?

Turn to us today! Drug GMP Report is prepared with subscribers in mind. Its main goal is to support one in maintaining a competitive edge. This newsletter has the insights and latest information one must know to ensure processes, procedures and controls are compliant.

Each issue of Drug GMP Report will bring subscribers the latest news on:

?FDA inspections and warning letters, such as the agency's continuing focus on failures to document quality unit responsibilities
?Areas of increasing FDA oversight including cybersecurity and data integrity
?New traceability requirements as the FDA implements the landmark Drug Supply Chain Security Act
?FDA's quality-related policy guidance
?International quality trends, including joint recognition of GMP inspections

For the past 20 years, manufacturers have relied on Drug GMP Report for the latest on the FDA's interpretation and enforcement of cGMPS.

Bonus! Subscribers also receive critical documents within each issue, such as draft or final guidances, 483s and warning letters, proposed rules, the full text of proposed legislation and more.
Subscribe now to start a one-year subscription (12 issues) to Drug GMP Report for only $1,045. Take advantage of our 100% Money-Back Guarantee, we're confident the value one gains from Drug GMP Report will pay for itself many times over.

Newsletter Details:
Drug GMP Report
An FDAnews Newsletter
https://www.fdanews.com/subscribe-now/drug-gmp-report

Subscription:
$1,045

Easy Ways to Register:
Online: https://www.fdanews.com/subscribe-now/drug-gmp-report
By phone: 888.838.5578 or 703.538.7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations

 

SOURCE FDAnews


These press releases may also interest you

at 11:23
Today, Samaritan's Purse deployed its Emergency Field Hospital to New York City, New York, where the local medical infrastructure is severely overwhelmed. In cooperation with the Federal Emergency Management Agency (FEMA), New York state officials,...

at 11:01
Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was...

at 11:00
As the impact of the Coronavirus (COVID-19) is now felt worldwide, we want to assure our customers and partners that we are still here to support you. Zenner's operations remain open with regular operating hours. Zenner's number one priority is...

at 10:13
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg...

at 10:05
Merck , known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered soluble...

at 10:00
Amgen today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK (BEIJERINCK) study evaluating the efficacy and safety of Repatha® (evolocumab) in...



News published on 27 march 2020 at 02:00 and distributed by: